Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended
phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary
clinical activity profile of the RP2D of OBI-999 in patients with advanced solid tumors.